DexCom (NASDAQ:DXCM) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research note issued to investors on Tuesday.

Several other brokerages have also issued reports on DXCM. Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They issued an outperform rating and a $165.00 target price for the company. Citigroup boosted their price objective on DexCom from $148.00 to $161.00 and gave the company a buy rating in a research report on Wednesday, April 3rd. UBS Group boosted their price objective on DexCom from $153.00 to $163.00 and gave the company a buy rating in a research report on Wednesday, April 10th. Finally, Raymond James boosted their price objective on DexCom from $147.00 to $151.00 and gave the company a strong-buy rating in a research report on Tuesday, January 23rd. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $141.67.

DexCom Stock Down 9.9 %

Shares of DXCM opened at $124.34 on Tuesday. The firm has a market cap of $49.24 billion, a P/E ratio of 80.22, a P/E/G ratio of 2.37 and a beta of 1.20. The stock has a 50 day simple moving average of $131.13 and a two-hundred day simple moving average of $118.30. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a return on equity of 31.38% and a net margin of 16.82%. On average, analysts forecast that DexCom will post 1.76 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock worth $25,530,859 over the last quarter. 0.41% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DexCom

Hedge funds have recently bought and sold shares of the business. Capital World Investors increased its stake in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Norges Bank bought a new position in shares of DexCom during the fourth quarter valued at approximately $540,178,000. Artisan Partners Limited Partnership increased its stake in shares of DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. Capital Research Global Investors increased its stake in shares of DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of DexCom during the fourth quarter valued at approximately $231,773,000. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.